2020
Safety and effectiveness of coronary intravascular lithotripsy in eccentric calcified coronary lesions: a patient-level pooled analysis from the Disrupt CAD I and CAD II Studies
Blachutzik F, Honton B, Escaned J, Hill JM, Werner N, Banning AP, Lansky AJ, Schlattner S, De Bruyne B, Di Mario C, Dörr O, Hamm C, Nef HM. Safety and effectiveness of coronary intravascular lithotripsy in eccentric calcified coronary lesions: a patient-level pooled analysis from the Disrupt CAD I and CAD II Studies. Clinical Research In Cardiology 2020, 110: 228-236. PMID: 32948882, PMCID: PMC7862504, DOI: 10.1007/s00392-020-01737-3.Peer-Reviewed Original ResearchConceptsCoronary intravascular lithotripsyIntravascular lithotripsyCalcified coronary lesionsII studyResidual stenosisCoronary lesionsCAD IPooled patient-level analysisFinal residual stenosisPercent residual stenosisFlow-limiting dissectionPatient-level analysisPatient-level dataHospital MACEIVL useAcute gainClinical outcomesConcentric lesionsEccentric lesionsCalcified lesionsAbrupt closureReflow eventsResultsClinical successStenosisConcentric stenosis
2019
TCT-177 Long-Term Serial Functional Evaluation After Implantation of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold: The FANTOM II study
Saito Y, Bouras G, Abizaid A, Lutz M, Carrié D, Weber-Albers J, Anderson J, Lansky A. TCT-177 Long-Term Serial Functional Evaluation After Implantation of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold: The FANTOM II study. Journal Of The American College Of Cardiology 2019, 74: b176. DOI: 10.1016/j.jacc.2019.08.234.Peer-Reviewed Original ResearchTCT-27 Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses: The Disrupt CAD II Study
Ali Z, Nef H, Escaned J, Werner N, Banning A, Hill J, Montorfano M, Lefevre T, Stone G, Lansky A. TCT-27 Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses: The Disrupt CAD II Study. Journal Of The American College Of Cardiology 2019, 74: b27. DOI: 10.1016/j.jacc.2019.08.054.Peer-Reviewed Original Research
2008
A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W, Group C. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. Journal Of The American College Of Cardiology 2008, 51: 1543-1552. PMID: 18420096, DOI: 10.1016/j.jacc.2008.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicChromium AlloysClopidogrelCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDiabetes MellitusFemaleHumansMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsPolymersRiskThromboembolismTiclopidineTime FactorsConceptsPercutaneous coronary interventionTarget vessel revascularizationDrug-eluting stentsMajor adverse cardiac eventsMultivessel percutaneous coronary interventionTaxus drug-eluting stentsMyocardial infarctionAdjudicated deathAdverse cardiac eventsPrimary end pointSegment late lossSingle target lesionPre-specified subgroupsStent thrombosis ratesTreatment of SingleVessel revascularizationCardiac eventsCoronary interventionII studyThrombosis rateAngiographic analysisEpicardial vesselsTarget lesionsLate lossPatients